Related Experiment Videos
Toward tailored disease management for type 2 diabetes.
Arianne M J Elissen1, Inge G P Duimel-Peeters, Cor Spreeuwenberg
1Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University, The Netherlands. a.elissen@maastrichtuniversity.nl
The American Journal of Managed Care
|November 14, 2012
Summary
Disease management programs (DMPs) for type 2 diabetes show small average improvements. However, tailored care focusing on patient characteristics significantly benefits those with poorer initial health, enhancing cost-effectiveness.
Area of Science:
- Public Health
- Clinical Medicine
- Health Services Research
Background:
- Population-based disease management programs (DMPs) are implemented for type 2 diabetes.
- Assessing the differentiated effects of these programs on clinical outcomes is crucial for optimizing care delivery.
Purpose of the Study:
- To evaluate the varied impacts of Dutch DMPs for type 2 diabetes on key clinical indicators.
- To identify patient and process characteristics influencing DMP effectiveness.
Main Methods:
- Meta-analysis and meta-regression of data from 18 Dutch care groups (N=105,056) between 2008-2010.
- Analysis of changes in glycated hemoglobin, LDL, systolic blood pressure, and BMI over 20-24 months.
- Stratified analyses based on patient and process variables to explain outcome heterogeneity.
Main Results:
- Small average improvements observed across clinical indicators.
- Significant improvements noted in patients with poorer initial health status.
- Heterogeneity reduced by accounting for patient characteristics; longer follow-up diminished effects, while higher measurement frequency improved outcomes.
Conclusions:
- Tailored disease management, integrating patient specifics into care processes, shows potential for improving cost-effectiveness.
- Personalized self-management support is key to enhancing chronic care delivery for type 2 diabetes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...